Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Gains from Investment Securities (2018 - 2025)

Inmune Bio (INMB) has disclosed Gains from Investment Securities for 8 consecutive years, with $100000.0 as the latest value for Q3 2025.

  • Quarterly Gains from Investment Securities fell 87.99% to $100000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $100000.0 through Sep 2025, down 87.99% year-over-year, with the annual reading at $218425.0 for FY2025, 102.25% up from the prior year.
  • Gains from Investment Securities hit $100000.0 in Q3 2025 for Inmune Bio, up from $22000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $7.3 million in Q1 2025 to a low of $22000.0 in Q2 2025.
  • Historically, Gains from Investment Securities has averaged $2.8 million across 5 years, with a median of $832307.0 in 2024.
  • Biggest five-year swings in Gains from Investment Securities: soared 923.08% in 2023 and later tumbled 99.65% in 2025.
  • Year by year, Gains from Investment Securities stood at $4.1 million in 2021, then increased by 18.17% to $4.8 million in 2022, then increased by 13.52% to $5.5 million in 2023, then plummeted by 98.03% to $108000.0 in 2024, then decreased by 7.41% to $100000.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for INMB at $100000.0 in Q3 2025, $22000.0 in Q2 2025, and $7.3 million in Q1 2025.